Eli Lilly (LLY -2.40%) is one of today's biggest players in the erectile dysfunction space. Its drug Cialis garnered more than $1.9 billion in 2012, but how important is this single therapeutic to Lilly's total business? What are the competitive dynamics of the erectile dysfunction market, and how do Pfizer's (PFE -0.17%) Viagra and VIVUS' (VVUS) drug Stendra compare to Cialis? In this video, health care analyst Max Macaluso examines these issues for investors.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Who are the key players in the erectile dysfunction space?
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Pfizer
PFE
$24.20
(-0.17%)
$0.04
VIVUS
VVUS
Eli Lilly
LLY
$776.08
(-2.40%)
$-19.04
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Hims & Hers Stock Investors Need to Know This Before Buying or Selling This Growth Stock
Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash
Which Stock Will Dominate the Weight Management Market Through 2030?
3 No-Brainer Stocks to Buy for Under $100 Right Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.